Amgen packs up in Claudin6
Meanwhile, Torl BioTherapeutics appears to be catching up with BioNTech.
Pfizer shuffles its deck post-Seagen
The group’s B7-H4-targeting bispecific is out, in favour of Seagen’s ADC.
Meanwhile, Torl BioTherapeutics appears to be catching up with BioNTech.
The group’s B7-H4-targeting bispecific is out, in favour of Seagen’s ADC.
